Literature DB >> 3834790

Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group trial.

M J Ravry, G A Omura, R Birch.   

Abstract

Maytansine given in a 3-day course q3 weeks produced only five responses (3%) in 163 evaluable adults with advanced cancer. The dose schedule employed is not recommended for further study.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3834790     DOI： 10.1097/00000421-198504000-00007

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN： 0277-3732            Impact factor:   2.339


  6 in total

Review 1.  Potential of plant-derived natural products in the treatment of leukemia and lymphoma.

Authors:  David M Lucas; Patrick C Still; Lynette Bueno Pérez; Michael R Grever; A Douglas Kinghorn
Journal:  Curr Drug Targets       Date:  2010-07       Impact factor: 3.465

Review 2.  Targeting and extending the eukaryotic druggable genome with natural products: cytoskeletal targets of natural products.

Authors:  April L Risinger; Lin Du
Journal:  Nat Prod Rep       Date:  2019-11-25       Impact factor: 13.423

Review 3.  Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.

Authors:  Noam Pondé; Philippe Aftimos; Martine Piccart
Journal:  Curr Treat Options Oncol       Date:  2019-04-01

4.  A DM1-doped porous gold nanoshell system for NIR accelerated redox-responsive release and triple modal imaging guided photothermal synergistic chemotherapy.

Authors:  Pengcheng Xu; Ru Wang; Wenqian Yang; Yanyan Liu; Dongsheng He; Zixuan Ye; Daquan Chen; Yuan Ding; Jiasheng Tu; Yan Shen
Journal:  J Nanobiotechnology       Date:  2021-03-19       Impact factor: 10.435

Review 5.  Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics.

Authors:  Eunhee G Kim; Kristine M Kim
Journal:  Biomol Ther (Seoul)       Date:  2015-11-01       Impact factor: 4.634

Review 6.  Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products.

Authors:  Matthew Trendowski
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.